Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midodrine for orthostatic intolerance after total hip arthroplasty
ACTRN12620001267943Phase 4Terminated
- Sponsor
- Sir Charles Gairdner and Osborne Park Hospital Group
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in orthostatic intolerance comparing Midodrine with Placebo (2 arms). Primary endpoint: Successful first mobilization. Started Feb 2021; status: terminated.
02
Drugs
midodrine
03
Conditions
orthostatic intolerance
Beyond the preview
Go deeper on ACTRN12620001267943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001267943.